Related Experiment Video
Updated: Jan 31, 2026

Author Spotlight: Membrane Protein Reconstitution in Synthetic Cells
Published on: March 8, 2024
Isoforms of Ionotropic Glutamate Receptor GRIK2 Induce Senescence of Carcinoma Cells
Vikramjit K Zhawar1, Raj P Kandpal2, Raghbir S Athwal3
1Fels Institute for Cancer Research and Molecular Biology, Temple University School of Medicine, Philadelphia, PA, U.S.A.
Background:
The aberrant regulation of growth and proliferation is a key feature of carcinoma cells. In order to use molecular strategies to correct these defects toward therapeutic purposes, it is important to characterize the entire spectrum of causative molecules.
Materials And Methods:
By using gene transfer technique, SKOV3 ovarian carcinoma cells were transduced with an expression construct of glutamate receptor 6 (glutamate ionotropic receptor kainate type subunit 2, GRIK2) in retroviral vector PQCXIP. The senescence of transduced cells was subsequently characterized.
Results:
Our results demonstrated that retroviral transduction occurs with high frequency and transduced cells continue to proliferate, albeit at a significantly reduced rate, up to 39 days. Some transduced colonies stopped proliferating after 12 days, and none of the clones proliferated beyond 37 days. The doubling time for these transduced cells increased progressively until they reached a complete cell-cycle arrest. The proliferating cells were distinguished by bromodeoxyuridine incorporation and 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide assay. The growth and cell cycle arrest in transduced cells accompanied activation of senescence-associated β-galactosidase. Furthermore, we have demonstrated a decrease in the levels of active protein kinase B and increase in the abundance of inactive cyclin-dependent kinase 1.
Conclusion:
These results indicate involvement of GRIK2 in senescence and suggests GRIK2 as a potential target for therapeutic intervention of cancer cells.
Insights
Introducing glutamate receptor 6 (GRIK2) into ovarian carcinoma cells induced senescence, halting proliferation. This suggests GRIK2 is a potential therapeutic target for treating cancer by correcting aberrant cell growth.
Area of Science:
- Oncology
- Molecular Biology
- Cell Biology
Background:
- Aberrant regulation of cell growth and proliferation is a hallmark of carcinoma.
- Identifying causative molecules is crucial for developing molecular therapeutic strategies.
Purpose of the Study:
- To investigate the role of glutamate receptor 6 (GRIK2) in ovarian carcinoma cell senescence.
- To assess the potential of GRIK2 as a therapeutic target for cancer.
Main Methods:
- Gene transfer technique using retroviral vector PQCXIP to transduce SKOV3 ovarian carcinoma cells with GRIK2.
- Characterization of cell senescence, proliferation rates, and cell-cycle arrest in transduced cells.
- Analysis of senescence-associated β-galactosidase activity and levels of active protein kinase B and inactive cyclin-dependent kinase 1.
Main Results:
- High-frequency retroviral transduction of SKOV3 cells with GRIK2.
- Transduced cells exhibited reduced proliferation rates and eventual cell-cycle arrest.
- Senescence was confirmed by increased β-galactosidase activity and altered levels of key cell-cycle regulatory proteins (PKB, CDK1).
Conclusions:
- GRIK2 plays a role in inducing senescence in ovarian carcinoma cells.
- GRIK2 represents a potential therapeutic target for cancer intervention.
Related Concept Videos
Replicative Cell Senescence
Internal Receptors
Types of Receptors: Cell Surface Receptors
Receptor-mediated Endocytosis
Antiepileptic Drugs: Glutamate Antagonists
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...

